Third Line/Rescue HIV Treatment Research

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Show Archived (Historical) Articles

Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
New Treatment Paradigms for Treatment-Experienced Patients (November 13, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Optimizing Therapy for Patients With Multidrug-Resistant HIV (July 31, 2006)
To read PDF, click here
From Insight Medical Communications Inc.
New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients (May 15, 2006)
Coverage of the 4th European HIV Drug Resistance Workshop and the 12th Annual Conference of the British HIV Association
Free CME/CE credit available for physicians, nurses and pharmacists.
From The Body PRO
Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Four-NRTI Regimen May Provide Simple Option for Treatment-Experienced Patients on Unduly Complex or Toxic Treatment (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From The Body PRO
Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
From The Body PRO
Triple PI Therapy May Help Heavily Treatment-Experienced Patients, But Pill Burden a Concern (October 2004)
Quick recap of a study in JAIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com
Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
New Dosing Regimen for Ritonavir-Boosted Atazanavir in Treatment-Experienced Patients; Revisions Made to Packaging Insert (July 7, 2004)
From U.S. Food and Drug Administration
Salvage Therapy II Think Tank: Integration of Salvage Research Into Existing Networks and Structures (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: Meeting Summary (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: Proof of Concept Studies/Translational Research; New Hypotheses (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: Regulatory Issues and Challenges in Salvage Therapy (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: The Future of Salvage Therapy: Monitoring Systems for Patient Outcomes (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Little Difference Between Resistance Testing Methods in Treatment-Experienced Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Single-Drug Interruption May Be Useful in Identifying Still-Active Drugs in Heavily Treated Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Triple-PI Regimens for Rescue Treatment (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
Adding ddI Achieves Fall in Viral Load in HAART Patients With Resistance (September 14, 2003)
From aidsmap.com
Risk of Death Following Triple-Class Virological Failure (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
To Switch or Not to Switch: When Is It a Question? (September 2003)
Steven Deeks, M.D., offers his wisdom on what options remain for patients who have failed one, two or many HAART regimens.
In The PRN Notebook
Ritonavir-Boosted Atazanavir Demonstrates Comparable Viral Load Reduction to Kaletra (August 15, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Atazanavir in Treatment-Experienced Patients (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Tipranavir/Ritonavir's Resistance Profile in Multiple-Protease-Inhibitor-Experienced Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News
Atazanavir Resistance: Use as Second- or Third-Line PI Should Not Be Ruled Out (April 1, 2003)
Evidence that this drug in development may be more than a first-line treatment.
From aidsmap.com
Structured Treatment Interruption to Increase Response to Salvage Therapy (Spring 2003)
From STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project
The Context Study: Efficacy and Safety of GW433908/RTV in PI-Experienced Subjects With Virological Failure (24 Week Results) (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor-Experienced Patients: BI 1182.52 (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor-Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Pharmacokinetic Parameters of Atazanavir/Ritonavir When Combined to Tenofovir in HIV Infected Patients With Multiple Treatment Failures: A Substudy of Puzzle2-ANRS 107 Trial (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Salvage Strategies and STI at the 10th Annual Retrovirus Conference (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Safety Profile of Tenofovir DF in Treatment-Experienced Patients From Randomized, Placebo-Controlled Clinical Trials (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
Predictors of Long-Term Response to Therapy Resumption After Treatment Interruption in HIV-1 Infected Patients Failing Antiretroviral Therapy (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
International HIV Workshop on Management of Treatment-Experienced Patients (November 2002)
A summary of the workshop's presentations.
In Hopkins HIV Report
Data From the 14th International AIDS Conference: Treatment-Experienced Patients (October 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Expert Opinion From Barcelona: For Experienced Folks (September/October 2002)
In Positively Aware, from Test Positive Aware Network
Enfuvirtide in Combination With an Optimized Background Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO
Dual vs. Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure (July 10, 2002)
Adding a second protease inhibitor to a failing regimen brings favorable results, according to a nationwide study.
In Journal of the American Medical Association
Tenofovir DF: A 48-Week Final Analysis From a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Treatment-Experienced Patients (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Safety Profile of Tenofovir DF in Antiretroviral Treatment-Experienced Patients From Randomized, Double-Blind, Placebo-Controlled Clinical Trials (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Successful Intensification of Antiretroviral Therapy With Abacavir in Clinical Practice (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Anti-HIV Therapy Update: STI and Third-Line Therapy (March 2002)
In Project Inform Perspective, from Project Inform
Selected Highlights From Retrovirus: Medications for the Treatment Experienced (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Management of "Salvage" Antiretroviral Therapy (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Antiretroviral Therapy for Previously Treated Patients (December 2001)
Summary of an August 2001 New England Journal of Medicine editorial.
In Body Positive, from Body Positive
Efficacy of Lopinavir in Heavily Pretreated Patients (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Antiviral Activity and Tolerability of PEG-Intron in HIV Patients Failing HAART (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Impact of Treatment Interruption on Plasma Viral Load, CD4 Count and Virtual Phenotypes (Virco) in HIV Patients Who Failed Multiple Courses of Antiretroviral Therapy (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
FDA Discusses Trial Design for Salvage Therapy (April 2001)
In TAGline, from Treatment Action Group
FDA Gives Salvage Therapy Testing a Push Forward (March 23, 2001)
In AIDS Treatment News, from AIDS Treatment News
Treatment of Antiretroviral-Experienced Patients: New Data From the 8th Retrovirus Conference (March 1, 2001)
In Hopkins HIV Report
Amprenavir and Ritonavir: Intra-Individual Comparison of Different Doses and Influence of Concomitant NNRTI on Steady-State Pharmacokinetics in HIV-Infected Patients (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Randomized Salvage Therapy With Saquinavir-Ritonavir (SQV-RTV) Versus Saquinavir-Nelfinavir (SQV-NFV) for Highly Experienced HIV-Infected Patients (September 17, 2000)
In The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
New Drugs for the Treatment-Experienced Patient (September 2000)
In The PRN Notebook
Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
Prospective, Multicenter Study of ddI Plus Hydroxyurea Plus Efavirenz Plus Protease Inhibitor Salvage Therapy. One-Year of Follow-Up. (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
Response to Salvage With Efavirenz: Implications for Sequencing Antiretroviral Therapy (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
Responses to Salvage Combination Therapy With Efavirenz in Patients With HIV Who Have Failed Antiretroviral Therapy With a Protease Inhibitor (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
The Combination of Ritonavir and Amprenavir in Salvage Regimens Overcomes Clinically Multiple-Drug Resistant HIV (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
Conference Coverage: 3rd International Workshop on Salvage Therapy for HIV Infection (Summer 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Report From the 7th CROI: Management of the Treatment-Experienced Patient (March 2000)
In Hopkins HIV Report
More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.